search
Back to results

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Primary Purpose

Dystrophic Epidermolysis Bullosa

Status
Not yet recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
PTW-002 10 mg/g gel
Placebo
Sponsored by
Phoenicis Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dystrophic Epidermolysis Bullosa focused on measuring DDEB, RDEB, exon 73, Epidermolysis Bullosa, COL7A1 gene, DEB, collagen type VII protein, C7, Dominant Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa

Eligibility Criteria

4 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients, and/or their legal guardian(s), if the patient is under the legal age of consent, must provide written Informed Consent or Assent, in accordance with national and/or local laws, prior to the conduct of any study related procedures. In addition, if applicable, a minor child must provide informed Assent in accordance with national and/or local laws and in compliance with the recommendations of the approving Institutional Review Board.
  2. Male or female, ≥ 4 - 17 years of age at Screening for RDEB patients, and ≥ 4 years of age at Screening for DDEB patients.
  3. Have a confirmed diagnosis of RDEB or DDEB and at least one pathogenic mutation in exon 73 of the COL7A1 gene. Historical genetic data may be acceptable with Medical Monitor approval.
  4. Have at least one TWA that shows no signs of local infection, and contains a target lesion that is either new or has shown dynamic healing in the past and complies with the following additional criteria:

    1. surface area of the target lesion ranging from 5 to 30 cm2, located centrally in the selected TWA.
    2. exposed sub-epidermal tissue to allow absorption of the investigational medicinal product (IMP).
    3. no suspicion of current squamous cell carcinoma (SCC) upon visual inspection.
  5. Have a caregiver or support person available, who can follow study instructions in compliance with the protocol and attend study site visits with the patient as required, in the opinion of the Investigator.
  6. Female patients who have reached menarche and male patients must either practice true abstinence in accordance with their preferred and usual lifestyle, or agree to use acceptable, effective methods of contraception for up to 3 months following their last dose of IMP.

Exclusion Criteria:

  1. Pregnant or breast-feeding female.
  2. Hemoglobin level at Screening requiring transfusion. The patient may be rescreened when the condition is considered stable.
  3. Use of aminoglycosides, by any route of administration, except eye drops, 7 days or 5 half-lives, whichever is longer, prior to Baseline visit.
  4. Untreated carcinoma of the TWA or history of carcinoma within 5 years prior to Screening, except adequately treated cutaneous squamous or basal cell carcinoma.
  5. Life expectancy less than 6 months, as assessed by the Investigator.
  6. Current or known history of clinically significant hepatic or renal disease that in the opinion of the Investigator, could impact patient safety or study participation.
  7. Bleeding disorder or condition, requiring the use of anticoagulants to be confirmed by activated partial thromboplastin time (aPTT) by local lab within 48 hours of first treatment.
  8. Use of any investigational drug or device within 28 days or 5 half-lives of the Baseline visit, whichever is longer, or plans to participate in another study of a drug or device during the study period. The washout of 5 half-lives does not apply to gene and cell therapy.
  9. History of cell therapy requiring treatment with exclusionary medication.
  10. History of skin-based gene therapy to the TWA.

Sites / Locations

  • Stanford Health Care
  • UMass Memorial Medical Center
  • Cincinnati Children's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

PTW-002 10 mg/g gel

Placebo

Arm Description

PTW-002 poloxamer hydrogel for topical administration (cutaneous use), 10 mg/g gel

Matching placebo poloxamer hydrogel for topical administration (cutaneous use)

Outcomes

Primary Outcome Measures

Number of adverse events (AEs)/serious adverse events (SAEs)
Assessment of exon 73 exclusion in COL7A1 mRNA, measured by droplet digital polymerase chain reaction (ddPCR)

Secondary Outcome Measures

Change in uptake of PTW-002 by cells at the basement membrane by fluorescent in situ hybridization (FISH) analysis
Effect of PTW-002 on wound healing by change in wound size (surface area)
Effect of PTW-002 on skin strength by onset of (re)blistering of a healed wound
Systemic exposure through serum levels of PTW-002 after topical administration to the target wound area (TWA)
Effect of PTW-002 on the presence of collagen type VII protein measured by immunofluorescent staining
Effect of PTW-002 on the presence of anchoring fibrils measured by electron microscopy

Full Information

First Posted
September 1, 2022
Last Updated
March 29, 2023
Sponsor
Phoenicis Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT05529134
Brief Title
Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene
Official Title
A Double-blind, Randomized, Intra-patient Placebo- Controlled, Multiple Dose Study of PTW-002 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy, and Systemic Exposure in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa (DDEB / RDEB) Due to Mutation(s) in Exon 73 of the COL7A1 Gene
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
April 30, 2023 (Anticipated)
Primary Completion Date
April 30, 2024 (Anticipated)
Study Completion Date
July 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Phoenicis Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
A double-blind, randomized, intra-patient placebo- controlled, multiple dose study of PTW-002 evaluating safety, proof of mechanism, preliminary efficacy, and systemic exposure in patients with Dominant Dystrophic Epidermolysis Bullosa (DDEB) or Recessive Dystrophic Epidermolysis Bullosa (RDEB) due to mutation(s) in exon 73 of the COL7A1 gene. Up to two RDEB patients 4 to 17 years of age and up to 6 DDEB patients 4 years of age and older will be enrolled.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dystrophic Epidermolysis Bullosa
Keywords
DDEB, RDEB, exon 73, Epidermolysis Bullosa, COL7A1 gene, DEB, collagen type VII protein, C7, Dominant Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
8 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PTW-002 10 mg/g gel
Arm Type
Experimental
Arm Description
PTW-002 poloxamer hydrogel for topical administration (cutaneous use), 10 mg/g gel
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matching placebo poloxamer hydrogel for topical administration (cutaneous use)
Intervention Type
Drug
Intervention Name(s)
PTW-002 10 mg/g gel
Intervention Description
poloxamer hydrogel for topical administration
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
placebo poloxamer hydrogel for topical administration
Primary Outcome Measure Information:
Title
Number of adverse events (AEs)/serious adverse events (SAEs)
Time Frame
Baseline through Week 32
Title
Assessment of exon 73 exclusion in COL7A1 mRNA, measured by droplet digital polymerase chain reaction (ddPCR)
Time Frame
Week 4
Secondary Outcome Measure Information:
Title
Change in uptake of PTW-002 by cells at the basement membrane by fluorescent in situ hybridization (FISH) analysis
Time Frame
Week 4
Title
Effect of PTW-002 on wound healing by change in wound size (surface area)
Time Frame
Baseline through Week 16
Title
Effect of PTW-002 on skin strength by onset of (re)blistering of a healed wound
Time Frame
Baseline through Week 16
Title
Systemic exposure through serum levels of PTW-002 after topical administration to the target wound area (TWA)
Time Frame
Baseline through Week 32
Title
Effect of PTW-002 on the presence of collagen type VII protein measured by immunofluorescent staining
Time Frame
Week 8
Title
Effect of PTW-002 on the presence of anchoring fibrils measured by electron microscopy
Time Frame
Week 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients, and/or their legal guardian(s), if the patient is under the legal age of consent, must provide written Informed Consent or Assent, in accordance with national and/or local laws, prior to the conduct of any study related procedures. In addition, if applicable, a minor child must provide informed Assent in accordance with national and/or local laws and in compliance with the recommendations of the approving Institutional Review Board. Male or female, ≥ 4 - 17 years of age at Screening for RDEB patients, and ≥ 4 years of age at Screening for DDEB patients. Have a confirmed diagnosis of RDEB or DDEB and at least one pathogenic mutation in exon 73 of the COL7A1 gene. Historical genetic data may be acceptable with Medical Monitor approval. Have at least one TWA that shows no signs of local infection, and contains a target lesion that is either new or has shown dynamic healing in the past and complies with the following additional criteria: surface area of the target lesion ranging from 5 to 30 cm2, located centrally in the selected TWA. exposed sub-epidermal tissue to allow absorption of the investigational medicinal product (IMP). no suspicion of current squamous cell carcinoma (SCC) upon visual inspection. Have a caregiver or support person available, who can follow study instructions in compliance with the protocol and attend study site visits with the patient as required, in the opinion of the Investigator. Female patients who have reached menarche and male patients must either practice true abstinence in accordance with their preferred and usual lifestyle, or agree to use acceptable, effective methods of contraception for up to 3 months following their last dose of IMP. Exclusion Criteria: Pregnant or breast-feeding female. Hemoglobin level at Screening requiring transfusion. The patient may be rescreened when the condition is considered stable. Use of aminoglycosides, by any route of administration, except eye drops, 7 days or 5 half-lives, whichever is longer, prior to Baseline visit. Untreated carcinoma of the TWA or history of carcinoma within 5 years prior to Screening, except adequately treated cutaneous squamous or basal cell carcinoma. Life expectancy less than 6 months, as assessed by the Investigator. Current or known history of clinically significant hepatic or renal disease that in the opinion of the Investigator, could impact patient safety or study participation. Bleeding disorder or condition, requiring the use of anticoagulants to be confirmed by activated partial thromboplastin time (aPTT) by local lab within 48 hours of first treatment. Use of any investigational drug or device within 28 days or 5 half-lives of the Baseline visit, whichever is longer, or plans to participate in another study of a drug or device during the study period. The washout of 5 half-lives does not apply to gene and cell therapy. History of cell therapy requiring treatment with exclusionary medication. History of skin-based gene therapy to the TWA.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ramsey Johnson
Phone
978-726-1478
Email
ramsey@phoenicistx.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hal Landy, MD
Organizational Affiliation
Phoenicis Therapeutics
Official's Role
Study Director
Facility Information:
Facility Name
Stanford Health Care
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kunju J Sridhar
Email
kunju@stanford.edu
First Name & Middle Initial & Last Name & Degree
Peter Marinkovich, MD
Facility Name
UMass Memorial Medical Center
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01655
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Celia Hartigan
Email
Celia.Hartigan@umassmed.edu
First Name & Middle Initial & Last Name & Degree
Karen Wiss, MD
Facility Name
Cincinnati Children's Hospital
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bret Augsburger
Email
Bret.Augsburger@cchmc.org
First Name & Middle Initial & Last Name & Degree
Anne Lucky, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

We'll reach out to this number within 24 hrs